APOA1 and atherosclerosis: For example, Milasan et al. concluded that improving dermal lymphatic vessels permeability by intradermal apolipoprotein A-I treatment and promoting contraction frequency by systemic administration of VEGF-C before the onset of atherosclerosis in Ldlr−/− mice leads to the attenuation of atherosclerosis [123,127].